Conv. Plasma
Nigella Sativa

All favipiravir studies
Meta analysis
study COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting

Reddy et al., International Journal of General Medicine, doi:10.2147/IJGM.S349241, CTRI/2020/11/029263
May 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Prospective single-arm study of 1,083 patients receiving favipiravir in India, showing one death and no new safety issues.
Reddy et al., 3 May 2022, prospective, India, peer-reviewed, 19 authors, study period December 2020 - June 2021, trial CTRI/2020/11/029263. Contact:
This PaperFavipiravirAll
Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting
Pavan Kumar Reddy, Saiprasad Patil, Akash Khobragade, Akash Balki, Aneesh Raj, Mrunalini Kalikar, Raghavendra Reddy, Ravindra Shinde, Jayanthi Cr, Abhinandan Mutha, Nagaraju Boyilla, Girish C Rajadhyaksha, Niteen Karnik, Sagar Bhagat, Amol Pendse, Priyanka Dhage, Wen Wu, Shabbir Rangwala, Hanmant Barkate
International Journal of General Medicine, doi:10.2147/ijgm.s349241
To evaluate the safety and efficacy of favipiravir, which is prescribed for the treatment of patients with mild-to-moderate coronavirus disease 2019 (COVID-19) in India. Patients and Methods: This was a prospective, open-label, multicenter, single-arm postmarketing study conducted in India. Patients with mild-to-moderate COVID-19 received favipiravir (3600 mg [1800 mg orally twice daily] on the first day, followed by 800 mg orally twice daily, up to a maximum of 14 days) as a part of their treatment. The primary endpoints were to evaluate the safety of favipiravir by assessing the number of adverse events (AEs) and treatment-related AEs. The secondary endpoints were to evaluate the efficacy of favipiravir by assessing time to clinical cure, rate of clinical cure, time to pyrexia resolution, rate of oxygen requirement, and all-cause mortality. Results: A total of 1083 patients were enrolled in this study from December 2020 to June 2021. Adverse events were reported in 129 patients (11.9%), 116 (10.7%) of whom had mild AEs. Dose modification or withdrawal of favipiravir treatment was reported in four patients (0.37%). The median time to clinical cure and pyrexia resolution was 7 and 4 days, respectively. A total of 1036 patients (95.8%) exhibited clinical cure by day 14. Oxygen support was required by 15 patients (1.4%). One death was reported, which was unrelated to favipiravir. Conclusion: In the real-world setting, favipiravir was well-tolerated, and no new safety signals were detected.
Time to Resolution of Pyrexia The median time to resolution of pyrexia in the present study was 4 days. The Kaplan-Meier survival curve for time to resolution of pyrexia in the mITT population is presented in Figure 4 . Additional details on subgroups are provided in the Supplementary Results. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure SP, SB, PD, AP, WW, SR, HB are full time employee of Glenmark Pharmaceuticals Ltd. PKR reports grants from Glenmark, during the conduct of the study. MK reports personal fees from Glenmark limited, during the conduct of the study. The authors report no other conflicts of interest in this work.
Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering, doi:10.1016/j.eng.2020.03.007
Chang, Park, Kim, Park, Risk factors for disease progression in COVID-19 patients, BMC Infect Dis, doi:10.1186/s12879-020-05144-x
Chen, Zhang, Huang, Favipiravir versus arbidol for COVID-19: a randomized clinical trial, medRxiv, doi:10.3389/fphar.2021.683296
Dabbous, Abd-Elsalam, El-Sayed, Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study, Arch Virol, doi:10.1007/s00705-021-04956-9
Furuta, Gowen, Takahashi, Shiraki, Smee et al., Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res, doi:10.1016/j.antiviral.2013.09.015
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B Phys Biol Sci, doi:10.2183/pjab.93.027
Ivashchenko, Dmitriev, Vostokova, AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a phase II/III multicenter randomized clinical trial, Clin Infect Dis, doi:10.1093/cid/ciaa1176
Lou, Liu, Yao, Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial, Eur J Pharm Sci, doi:10.1016/j.ejps.2020.105631
López-Medina, López, Hurtado, Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2021.3071
Nasir, Murshed, Nazneen, Talha, Survival and biomarkers of COVID-19 patients treated with remdesivir and favipiravir in ICU during the peak of pandemic: a single center study in Bangladesh, J Pharma Res Int
Nasir, Perveen, Saha, Talha, Selina et al., Systematic review on repurposing use of favipiravir against SARS-CoV-2, Journal of General Medicine, doi:10.2147/IJGM.S349241
Panchal, Venugopal, Vora, P5-64: therapeutic effectiveness & safety of favipiravir in COVID-19 patients with risk factors for mortality: clinical practice experience from India, Respirology, doi:10.1111/resp.14150_271
Panchal, Venugopal, Vora, P5-70: effectiveness of favipiravir in COVID-19 patients with multiple (≥2) or less (<2) comorbidities: a real word experience from India, Respirology
Panchal, Venugopal, Vora, P5-93: therapeutic effectiveness and tolerability of favipiravir in mild COVID-19: real world experience from India, Respirology, doi:10.1111/resp.14150_300
Perlman, Another decade, another coronavirus, N Engl J Med, doi:10.1056/NEJMe2001126
Perveen, Nasir, Murshed, Naznin, Ahmed, Remdesivir and favipiravir changes hepato-renal profile in COVID-19 patients: a cross sectional observation in Bangladesh, Journal of General Medicine, doi:10.18535/ijmsci/v8i01.03
Perveen, Nasir, Talha, Selina, Islam, Systematic review on current antiviral therapy in COVID-19 pandemic, Med J Malaysia
Rattanaumpawan, Jirajariyavej, Lerdlamyong, Palavutitotai, Saiyarin, Real-world experience with favipiravir for treatment of COVID-19 in Thailand: results from a multicenter observational study, medRxiv
Turcotte, Meisenberg, Macdonald, Risk factors for severe illness in hospitalized Covid-19 patients at a regional hospital, PLoS One, doi:10.1371/journal.pone.0237558
Udwadia, Singh, Barkate, Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int J Infect Dis, doi:10.1016/j.ijid.2020.11.142
Weinreich, Sivapalasingam, Norton, REGEN-COV antibody combination and outcomes in outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2035002
{ 'indexed': {'date-parts': [[2022, 5, 2]], 'date-time': '2022-05-02T12:41:12Z', 'timestamp': 1651495272822}, 'reference-count': 25, 'publisher': 'Informa UK Limited', 'license': [ { 'start': { 'date-parts': [[2022, 5, 1]], 'date-time': '2022-05-01T00:00:00Z', 'timestamp': 1651363200000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': ''}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.2147/ijgm.s349241', 'type': 'journal-article', 'created': {'date-parts': [[2022, 5, 2]], 'date-time': '2022-05-02T12:00:30Z', 'timestamp': 1651492830000}, 'page': '4551-4563', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with ' 'Mild-to-Moderate COVID-19 in a Real-World Setting', 'prefix': '10.2147', 'volume': 'Volume 15', 'author': [ {'given': 'Pavan Kumar', 'family': 'Reddy', 'sequence': 'first', 'affiliation': []}, {'given': 'Saiprasad', 'family': 'Patil', 'sequence': 'additional', 'affiliation': []}, {'given': 'Akash', 'family': 'Khobragade', 'sequence': 'additional', 'affiliation': []}, { 'suffix': 'Snr', 'given': 'Akash', 'family': 'Balki', 'sequence': 'additional', 'affiliation': []}, {'given': 'Aneesh', 'family': 'Raj', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mrunalini', 'family': 'Kalikar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Raghavendra', 'family': 'Reddy', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ravindra', 'family': 'Shinde', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jayanthi', 'family': 'CR', 'sequence': 'additional', 'affiliation': []}, {'given': 'Abhinandan', 'family': 'Mutha', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nagaraju', 'family': 'Boyilla', 'sequence': 'additional', 'affiliation': []}, { 'suffix': 'Snr', 'given': 'Girish C', 'family': 'Rajadhyaksha', 'sequence': 'additional', 'affiliation': []}, {'given': 'Niteen', 'family': 'Karnik', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sagar', 'family': 'Bhagat', 'sequence': 'additional', 'affiliation': []}, {'given': 'Amol', 'family': 'Pendse', 'sequence': 'additional', 'affiliation': []}, { 'suffix': 'Snr', 'given': 'Priyanka', 'family': 'Dhage', 'sequence': 'additional', 'affiliation': []}, {'given': 'Wen', 'family': 'Wu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shabbir', 'family': 'Rangwala', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hanmant', 'family': 'Barkate', 'sequence': 'additional', 'affiliation': []}], 'member': '301', 'published-online': {'date-parts': [[2022, 5]]}, 'reference': [ { 'key': 'ref1', 'doi-asserted-by': 'publisher', 'first-page': '760', 'DOI': '10.1056/NEJMe2001126', 'volume': '382', 'author': 'Perlman', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'ref2', 'unstructured': 'World Health Organization. WHO Coronavirus (COVID-19) Dashboard. ' 'Available from: Accessed October 25, 2021.'}, { 'key': 'ref3', 'doi-asserted-by': 'publisher', 'first-page': '446', 'DOI': '10.1016/j.antiviral.2013.09.015', 'volume': '100', 'author': 'Furuta', 'year': '2013', 'journal-title': 'Antiviral Res'}, { 'key': 'ref4', 'doi-asserted-by': 'publisher', 'first-page': '449', 'DOI': '10.2183/pjab.93.027', 'volume': '93', 'author': 'Furuta', 'year': '2017', 'journal-title': 'Proc Jpn Acad Ser B Phys Biol Sci'}, { 'key': 'ref5', 'unstructured': 'WHO R&D Blueprint COVID 19 Experimental Treatments. COVID classification ' 'of treatment types; 2020. Available from: ' ' ' 'Accessed August 16, 2021.'}, { 'key': 'ref6', 'doi-asserted-by': 'publisher', 'first-page': '62', 'DOI': '10.1016/j.ijid.2020.11.142', 'volume': '103', 'author': 'Udwadia', 'year': '2021', 'journal-title': 'Int J Infect Dis'}, { 'key': 'ref7', 'doi-asserted-by': 'crossref', 'unstructured': 'Panchal S, Venugopal K, Vora A, et al.\xa0 P5-93: therapeutic ' 'effectiveness and tolerability of favipiravir in mild COVID-19: real ' 'world experience from India. Respirology. 2021;26(S3):194. ' 'doi:10.1111/resp.14150_300', 'DOI': '10.1111/resp.14150_300'}, { 'key': 'ref8', 'doi-asserted-by': 'crossref', 'unstructured': 'Panchal S, Venugopal K, Vora A, et al. \xa0 P5-64: therapeutic ' 'effectiveness & safety of favipiravir in COVID-19 patients with risk ' 'factors for mortality: clinical practice experience from India. ' 'Respirology. 2021;26(S3):182. doi:10.1111/resp.14150_271', 'DOI': '10.1111/resp.14150_271'}, { 'key': 'ref9', 'unstructured': 'Central Drugs Standard Control Organisation, India. List of new drugs ' 'approved in the year 2020. Available from: ' ' ' 'Accessed August 16, 2021.'}, { 'key': 'ref10', 'first-page': '747', 'volume': '29', 'author': 'Nasir', 'year': '2020', 'journal-title': 'Mymensingh Med J'}, { 'key': 'ref11', 'first-page': '710', 'volume': '75', 'author': 'Perveen', 'year': '2020', 'journal-title': 'Med J Malaysia'}, { 'key': 'ref12', 'unstructured': 'Favipiravir Observational Study Group. Preliminary report of the ' 'favipiravir observational study in Japan; 2020. Available from: ' ' ' 'Accessed August 13, 2021.'}, { 'key': 'ref13', 'doi-asserted-by': 'publisher', 'first-page': '1192', 'DOI': '10.1016/j.eng.2020.03.007', 'volume': '6', 'author': 'Cai', 'year': '2020', 'journal-title': 'Engineering'}, { 'key': 'ref14', 'volume': '2020', 'author': 'Rattanaumpawan', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': 'ref15', 'doi-asserted-by': 'publisher', 'author': 'Chen', 'year': '2020', 'journal-title': 'medRxiv', 'DOI': '10.3389/fphar.2021.683296'}, { 'key': 'ref16', 'doi-asserted-by': 'publisher', 'first-page': '238', 'DOI': '10.1056/NEJMoa2035002', 'volume': '384', 'author': 'Weinreich', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': 'ref17', 'doi-asserted-by': 'publisher', 'first-page': '1426', 'DOI': '10.1001/jama.2021.3071', 'volume': '325', 'author': 'López-Medina', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': 'ref18', 'first-page': '14', 'volume': '32', 'author': 'Nasir', 'year': '2020', 'journal-title': 'J Pharma Res Int'}, { 'key': 'ref19', 'doi-asserted-by': 'crossref', 'unstructured': 'Panchal S, Venugopal K, Vora A, et al. \xa0 P5-70: effectiveness of ' 'favipiravir in COVID-19 patients with multiple (≥2) or less (<2) ' 'comorbidities: a real word experience from India. Respirology. ' '2021;26(S3):184.', 'DOI': '10.1111/resp.14150_277'}, { 'key': 'ref20', 'doi-asserted-by': 'publisher', 'first-page': '531', 'DOI': '10.1093/cid/ciaa1176', 'volume': '73', 'author': 'Ivashchenko', 'year': '2021', 'journal-title': 'Clin Infect Dis'}, { 'key': 'ref21', 'doi-asserted-by': 'publisher', 'first-page': '445', 'DOI': '10.1186/s12879-020-05144-x', 'volume': '20', 'author': 'Chang', 'year': '2020', 'journal-title': 'BMC Infect Dis'}, { 'key': 'ref22', 'doi-asserted-by': 'publisher', 'first-page': 'e0237558', 'DOI': '10.1371/journal.pone.0237558', 'volume': '15', 'author': 'Turcotte', 'year': '2020', 'journal-title': 'PLoS One'}, { 'key': 'ref23', 'doi-asserted-by': 'publisher', 'first-page': '949', 'DOI': '10.1007/s00705-021-04956-9', 'volume': '166', 'author': 'Dabbous', 'year': '2021', 'journal-title': 'Arch Virol'}, { 'key': 'ref24', 'doi-asserted-by': 'publisher', 'first-page': '105631', 'DOI': '10.1016/j.ejps.2020.105631', 'volume': '157', 'author': 'Lou', 'year': '2021', 'journal-title': 'Eur J Pharm Sci'}, { 'key': 'ref25', 'doi-asserted-by': 'publisher', 'first-page': '5196', 'DOI': '10.18535/ijmsci/v8i01.03', 'volume': '8', 'author': 'Ara Perveen', 'year': '2021', 'journal-title': 'ijmsci'}], 'container-title': 'International Journal of General Medicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': '', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': '', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 5, 2]], 'date-time': '2022-05-02T12:00:35Z', 'timestamp': 1651492835000}, 'score': 1, 'resource': { 'primary': { 'URL': ''}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 5]]}, 'references-count': 25, 'URL': '', 'relation': {}, 'ISSN': ['1178-7074'], 'subject': ['General Medicine'], 'container-title-short': 'IJGM', 'published': {'date-parts': [[2022, 5]]}}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop